Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lincoln Pharmaceuticals's current ratio for the quarter that ended in Jun. 2026 was .
Lincoln Pharmaceuticals has a current ratio of . It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Lincoln Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Lincoln Pharmaceuticals's Current Ratio or its related term are showing as below:
NSE:LINCOLN'
s Current Ratio Range Over the Past 10 Years
Min: 1.68 Med: 3.78 Max: 5.25
Current: 5.25
During the past 13 years, Lincoln Pharmaceuticals's highest Current Ratio was 5.25. The lowest was 1.68. And the median was 3.78.
NSE:LINCOLN's Current Ratio is ranked better than 86.77% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs NSE:LINCOLN: 5.25
Lincoln Pharmaceuticals (NSE:LINCOLN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lincoln Pharmaceuticals Current Ratio Related Terms
Lincoln Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lincoln Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lincoln Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹604.85 is trading 17.4% below its estimated GF Value™ of ₹732.51.
GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:LINCOLN:
Current Ratio:
GF Value™: ₹732.51 vs. price of ₹604.85 (17.4% below fair value)
No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
84GF Score
Get the complete analysis for NSE:LINCOLN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LINCOLN has been successfully added to your 
